PGEN
Precigen, Inc. Health Care Pharmaceutical Preparations Russell 3000
$6.94Close
$2.5BMarket cap
$3.10 – $8.5652-week range
Nov 4, 2026Next report · after the close
Highlights
Strengths
- Leading the market RS 91 · stronger than 91% of stocks over 12 months
Cautions
- Trend not confirmed 7 of 8 conditions · under the 50-day
- Results soon Nov 4, 2026, in 3 days
- Financial distress Altman Z″ in the distress zone
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
19%
1wk
up 12.1%
price change
1mo
down 18.9%
price change
12-month return
up 71%
market up 11% ·
its own up 62%
F-score
—
— Not assessed
Altman Z
-11.81
Elevated risk
P/E
—
price / earnings
PEG
—
P/E / EPS growth
P/B
117.5×
price / book
Earnings yield
down 4.4%
EBIT / enterprise value
Cheaper than
9%
of the market · expensive
Revenue growth
up 147%
year on year
EPS growth
—
latest quarter
Sales growth
up 6323%
latest quarter · +4689 pts
ROE
down 843%
return on equity
Free cash margin
down 928%
-$89.8M FCF
D/E
4.46
long-term debt / equity
Net debt / EBITDA
—
Interest cover
—EBIT / interest
Piotroski tests
Repair signals
- Revenue reaccelerating (-37% then +147%)
Trade setup
ATR%
6.3%
$0.44 a day · 2×ATR $6.07
RS
91 / 99
vs the universe
Trend
7 / 8
under the 50-day
Relative volume
1.7×
vs 50-day average
Up/down volume
1.02
50 sessions
Implied move
—
no option chain · report Nov 4, 2026
Trend template · 7 of 8
- Price above the 50-day average: fails
Screen verdict
Did not qualify for any screen.
Warning signs
- Bankruptcy model reads distressed The Altman score sits inside the range historically associated with financial distress. It is used here only to exclude, never to rank, and it is a statistical band rather than a prediction about this company.
- Shareholders diluted The share count rose 20.8% over the year, from 293m to 354m shares. Each existing share owns a smaller fraction of the company than it did a year ago.
Last reported
Aug 4, 2026
Last shock
Oct 5, 2026-9% in one session1.9× volumeno filing matched-10% since
Financials
- Net -2588%
- Free cash -928%
- Cash
- Long-term debt
| FY2020Dec 31, 2020 | FY2021Dec 31, 2021 | FY2022Dec 31, 2022 | FY2023Dec 31, 2023 | FY2024Dec 31, 2024 | FY2025Dec 31, 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $32.0M | $14.3M | $26.9M | $6.2M | $3.9M | $9.7M |
| Operating income | — | — | — | -$99.8M | -$135.0M | -$110.5M |
| Net income | -$170.5M | -$92.2M | $28.3M | -$95.9M | -$126.2M | -$250.6M |
| Net margin | -533% | -646% | 105% | -1541% | -3215% | -2588% |
| Earnings per share | -$1.02 | -$0.47 | $0.14 | -$0.39 | -$0.47 | -$0.80 |
| Free cash flow | -$84.5M | -$63.0M | -$70.0M | -$68.5M | -$76.8M | -$89.8M |
| Free cash margin | -264% | -442% | -260% | -1100% | -1956% | -928% |
| Cash | $51.8M | $36.4M | $4.9M | $7.6M | $29.5M | $30.2M |
| Long-term debt | $171.5M | $179.9M | $0 | — | $0 | $93.2M |
| Shareholders' equity | $67.2M | $107.3M | $126.3M | $118.5M | $38.5M | $20.9M |
| Shares outstanding | 187.66m | 206.74m | 208.15m | 248.92m | 292.87m | 353.91m |
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Aug 4, 2026 | Quarterly ↗ | Jun 30, 2026 | 35d |
| May 13, 2026 | Quarterly ↗ | Mar 31, 2026 | 43d |
| Mar 25, 2026 | Annual ↗ | Dec 31, 2025 | 84d |
| Nov 13, 2025 | Quarterly ↗ | Sep 30, 2025 | 44d |
| Aug 12, 2025 | Quarterly ↗ | Jun 30, 2025 | 43d |
| May 14, 2025 | Quarterly ↗ | Mar 31, 2025 | 44d |
| Mar 19, 2025 | Annual ↗ | Dec 31, 2024 | 78d |
| Nov 14, 2024 | Quarterly ↗ | Sep 30, 2024 | 45d |
| Aug 14, 2024 | Quarterly ↗ | Jun 30, 2024 | 45d |
| May 14, 2024 | Quarterly ↗ | Mar 31, 2024 | 44d |
| Mar 19, 2024 | Annual ↗ | Dec 31, 2023 | 79d |
| Nov 9, 2023 | Quarterly ↗ | Sep 30, 2023 | 40d |
Current reports
| Filed | Disclosed |
|---|---|
| Aug 4, 2026 | Results ↗ |
| Jun 24, 2026 | Director or officer change · Shareholder vote ↗ |
| May 13, 2026 | Results ↗ |
| Mar 25, 2026 | Results ↗ |
| Nov 13, 2025 | Results ↗ |
| Sep 17, 2025 | Unregistered share sale ↗ |
| Sep 3, 2025 | Material agreement · New obligation · Regulation FD ↗ |
| Aug 18, 2025 | Regulation FD ↗ |
| Aug 18, 2025 | Material agreement ↗ |
| Jun 30, 2025 | Director or officer change · Shareholder vote ↗ |
| May 14, 2025 | Results ↗ |
| Mar 19, 2025 | Results ↗ |